Cargando…
Interim thymus and activation regulated chemokine versus interim (18)F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation
Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid‐treatment interim TARC (iTARC) with interim (18)F‐fluorodeoxyglucose positron‐emission tomography (iPET) imaging to predict...
Autores principales: | Plattel, Wouter J., Visser, Lydia, Diepstra, Arjan, Glaudemans, Andor W. J. M., Nijland, Marcel, van Meerten, Tom, Kluin‐Nelemans, Hanneke C., van Imhoff, Gustaaf W., van den Berg, Anke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383815/ https://www.ncbi.nlm.nih.gov/pubmed/32106342 http://dx.doi.org/10.1111/bjh.16514 |
Ejemplares similares
-
Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma
por: Veldman, Johanna, et al.
Publicado: (2021) -
Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP
por: Jeon, Young‐Woo, et al.
Publicado: (2019) -
Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020) -
Relationship between semiquantitative (18)F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma
por: Kahle, X. U., et al.
Publicado: (2019) -
Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial
por: Doorduijn, Jeanette K., et al.
Publicado: (2020)